Engineered extracellular vesicles show promise in targeting cancer cells and immunosuppressive stromal cells, offering a ...

FMC63, an IgG2a mouse monoclonal antibody, targets CD19. To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs ...

VIR-5818 is under clinical development by Vir Biotechnology and currently in Phase II for Metastatic Colorectal Cancer.